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Background: Chronic progressive mesangioproliferative nephropathy represents a major cause of end-stage renal
disease worldwide. Until now, effective approaches to stop or even slow its progression are limited. We tested the
effects of an inhibitor of PDGF receptor, abl and c-kit tyrosine kinases, Imatinib, in a chronic progressive model of
mesangioproliferative glomerulosclerosis.
Methods: Anti-thy1 glomerulosclerosis was induced by injection of anti-thy1 antibody into uninephrectomized Wistar
rats. One week after disease induction, according to the degree of proteinuria, animals were stratified and assigned to
chronic glomerulosclerosis (cGS) and cGS plus Imatinib (10 mg/kg body weight/day). In week 20, renoprotective
actions of Imatinib were analyzed by a set of functional, histological and molecular biological parameters.
Results: Untreated cGS rats showed elevation of systolic blood pressure and marked progression in proteinuria, renal
fibrosis, cell infiltration, cell proliferation and function lost. Administration of Imatinib went along significantly with
lower systolic blood pressure (−10 mmHg) and proteinuria (−33%). Imatinib administration was paralled by significant
reductions in tubulointerstitial accumulation of matrix proteins (−44%), collagen I deposition (−86%), expression of
TGF-beta1 (−30%), production of fibronectin (−23%), myofibroblast differentiation (−87%), macrophage infiltration
(−36%) and cell proliferation (−45%), respectively. In comparison with untreated cGS animals, Imatinib therapy lowered
also blood creatinine (−41%) and blood urea concentrations (−36%) and improved creatinine clearance (+25%).
Glomerular fibrotic changes were lowered moderately by Imatinib.
Conclusions: Therapy with Imatinib limits the progressive course of chronic anti-thy1 glomerulosclerosis towards
tubulointerstitial fibrosis and renal insufficiency. This was paralleled by direct and indirect sign of TGF-β1 and PDGF
inhibition. The findings suggest that the pharmacological principal of inhibition of tyrosine kinases with drugs such as
Imatinib might serve as approach for limiting progression of human mesangioproliferative glomerulosclerosis.
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IgA nephropathy, a mesangial proliferative glomeruloneph-
ritis, is the most common primary glomerulonephritis
worldwide, and as many as 20-30% of patients with IgA ne-
phropathy progress to end-stage renal failure after 20–
25 years [1-4]. It is characterized by in the beginning phase* Correspondence: harm.peters@charite.de
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distribution, and reproduction in any mediumwith expansion of glomerular mesangial matrix and me-
sangial cell proliferation, and a subsequent progression
phase with glomerulosclerosis, tubulointerstitial fibrosis
and ongoing loss in renal function, which is a hallmark of
many chronic glomerulonephritis [5]. The progress from
glomerulonephritis to end-stage renal disease and the need
for renal replacement therapy can even be seen when the
initial glomerulonephritic phase has been resolved, sug-
gesting a self-perpetuated and intrarenal mechanism is ope-
rating during the disease progression.Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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man diseases have shown that persistent overexpression
of the cytokines transforming growth factor-β (TGF-β)
and platelet-derived growth factor (PDGF) are key
markers and mediators of tissue matrix accumulation
and cell proliferation in progressive renal disease [6,7].
Prominent characteristics of chronic renal disease are ex-
pansion of extracellular matrix expansion, renal cell prolif-
eration and cell infiltration as well as the appearance of
“activated” fibroblasts characterized by α-smooth muscle
actin (SMA) [8,9]. The origin of these myofibroblasts is
unclear but may result from growth factor-mediated dif-
ferentiation of resident mesenchymal cells or recruitment
of microvascular pericytes. Recent evidence has suggested
that TGF-β induces the differentiation of resident mesen-
chymal cells to myofibroblast and PDGF appears to affect
pericyte differentiation and recruitment [10,11]. In turn,
specific inhibitions of TGF-β and PDGF pathways and ac-
tion have increasingly been explored as therapeutic ap-
proaches for progressive renal disease.
Imatinib mesylate (formerly STI 571; Glivec/Gleevec)
inhibits Abelson (c-Abl)- and c-kit kinases, as well as
PDGF receptor α and β [12]. It has been already used
clinically in treatment of diseases with abl- and c-kit ki-
nases overexpression, such as gastrointestinal stromal
tumors and chronic myeloid leukemia [13]. In vitro
studies have demonstrated that Bcr-Abl might be a
down-stream mediator of TGF-β signalling in fibroblasts
[14]. Imatinib has shown anti-fibrotic effects in different
animal models with organ fibrosis, including acute anti-
thy1 glomerulonephritis of the rat [15].
In this study, we examined the effects of Imatinib in a
model of progressive mesangioprolifertive glomerulos-
clerosis. The novel finding of this study is that expands
from the acute anti-thy1 glomerulonephritis into a anti-
thy1-induced chronic-progressive glomerulosclerosis mo-
del of human mesangioproliferative nephropathy as a
leading cause of end-stage kidney disease worldwide.
In this model, injection of high dose anti-thy1 antibody
into uninephrectomized rats leads to a brief period of
acute mesangioproliferative glomerulonephritis which is
followed by an autonomous progression towards glo-
merulosclerosis, tubulointerstitial fibrosis and renal
insufficiency over months. An acute, reversible, and 4-
week course of the disease occurs when a relatively low
dose of anti-thy1 antibody is injected into animals with
two kidneys, where the overproduction of TGF-β is
transient [16].
Treatment with Imatinib was started 1 week after anti-
body injection. Effects of Imatinib treatment on protein-
uria, blood pressure, glomerular and tubulointerstitial
fibrosis, molecular markers of TGF-β and PDGF path-
ways and renal function were determined in week 20
after disease induction.Methods
Materials
All materials, chemicals and cell culture media used, if
not stated differently, were purchased from Sigma
Chemical-Aldrich Co. (Taufkirchen, Germany).
Animals and model of anti-thy1-induced chronic-
progressive glomerulosclerosis
Male Wistar rats (150–180 g, Charles River, Sulzfeld,
Germany) were caged in a constant temperature room
with a 12 h dark/12 h light cycle and fed a normal pro-
tein diet (22.5% protein, Altromin, Lage, Germany) for
at least 3 days before the start of the experiment to
allow equilibration. The animals were visited daily, and
the consumption of food and drinking water and body
weight were monitored every 2–3 days.
Anti-thy1-induced chronic-progressvie glomerulos-
clerosis (cGS) was induced by intravenously injecting
the monoclonal antibody mAb 1-22-3 (5 mg/kg body
weight in phosphate-buffered saline [PBS], pH =7.4)
three days after uni-nephrectomy as previously de-
scribed [17]. mAb 1-22-3 antibody binds to a thy1-like
antigen on mesangial cells and causes a fast complement-
and NO-dependent mesangial cell lysis within the next
24 h [18]. The uninephrectomy being performed before
anti-thy1 antibody injection is related to the chronic pro-
gression of cGS, since the glomerular disease resolves over
approximately 4 weeks in animals with two kidneys. Con-
trol animals with and without uninephrectomy were
injected with equal volumes of PBS only.
Animal care and treatment were in conformity with
the ARRIVE (Animal Research: Reporting In Vivo Ex-
periments) guidelines being developed by the NC3Rs
and approved by local authorities (animal experiments,
Landesamt für Arbeitsschutz, Gesundheitsschutz und
technische Sicherheit Berlin).
Study groups and design
Nonnephrectomized animals injected with PBS (2-K Con-
trol, n = 4) and uninephrectomized animals injected with
PBS (1-K Control, n = 4) served as controls. On the basis
of the actual 24-h proteinuria achieved one week after
anti-thy1 antibody injection, the diseased animals were
stratified assigned to the uni-nephrectomized, anti-thy1-
injected animals, no treatment (cGS, n = 11) and uni-
nephrectomized, anti-thy1-injected animals treated with
Imatinib (cGS + Imatinib, n = 11) groups.
Treatments were started seven days after antibody injec-
tion, to avoid interference with the induction of disease by
anti-thy1 antibody. Imatinib is chemically designated as 4-
[(4-methyl-1-piperazinyl)medthyl]-N-[4-methyl-3-[[4-(3-py
ridinyl)-2-pyrimidinyl]amino]-phenyl] benzamide methane
sulfonate [12]. Imatinib is designed to specifically interact
with the adenosine triphosphate (ATP)-binding site of
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sine kinases Bcr-Abl, PDGF receptors, and c-kit [12]. It
was given with the food at a daily dose of 10 mg/kg body
weight. The dose was chosen on the basis of previous re-
ports showing that this dose reduced diabetic nephropathy
progression in rats [19]. The drug-containing food was
produced by mixing Imatinib mesylate with the flour of
the standard rat chow (22.5% protein, A1311, Altromin),
and water was added to form pellets which were subse-
quently given to the animals after being air-dried [17].
In week 20, i.e. after 19 weeks of treatment, the actions of
tyrosine kinases signal transduction inhibition by Imatinib
on proteinuria, systolic blood pressure, matrix protein
expansion, macrophage infiltration, cell proliferation and
kidney function were determined. Glomerular and tu-
bulointerstitial changes were analyzed separately. Glomeruli
were isolated by a graded sieving technique. Since the renal
cortex consists mainly of tubulointerstitial tissue (>95%), it
was used as representative for the tubulointerstitium. Ana-
lysis of fibrosis involved a computer-based histological cal-
culation of the matrix and collagen I actually accumulated
as well as molecular analysis of the expression of the key
fibrosis marker and mediator TGF-β1, the matrix protein
fibronectin which indicates matrix protein synthesis,
and the tissue inhibitor of metalloproteinase-1 (TIMP-1)
as a marker of matrix protein degradation. Tubuloin-
terstitial and glomerular myofibroblast differentiation,
macrophage infiltration and cell proliferation were ana-
lyzed by immunohistochemistry using an α-SMA-, ED1-
or a Proliferating-Cell-Nuclear-Antigen (PCNA) -antibody,
respectively. In addition, blood creatinine and urea con-
centrations, and calculated creatinine clearance served as
markers of renal function.Blood pressure and proteinuria
Systolic blood pressure was assessed in weeks 10 and 20 in
trained conscious animals using tail cuff plethysmography
as previously described [16]. 1, 8 and 19 weeks after disease
induction, animals were housed individually in metabolic
cages for 24-hour urine collection. Urinary protein was de-
termined by a pyrogallol red method [16] and is expressed
as mg protein/24 h.Sacrifice
The experiments were terminated by anesthetizing ani-
mals with 0.1 mg ketanest/ 0.01 mg xylazin per 100 g
body weight (Ketamin 10%, WDT, Garbsen, Germany;
Rompun 2%, Bayer Vital GmbH, Leverkusen; Germany).
Following laparotomy, blood was drawn from the ab-
dominal aorta into EDTA-coated tubes and kidneys were
subsequently perfused with 40 mL ice-cold PBS. Mate-
rials and tissues were subsequently processed as de-
scribed in the following sections.Renal function analysis
Spectrometrical enzyme-based assays were used to meas-
ure plasma and urine creatinine and plasma urea. Glom-
erular filtration rate (GFR) was calculated subsequently on
the basis of the corresponding urine volume and is
expressed as ml per minute per 100 g body weight [16].
Histology and immunohistochemistry
All microscopic examinations were performed in a
blinded fashion as previously reported [20]. For histo-
logical examination, cortical tissue was fixed in Carnoy’s
solution. Three-μm sections of paraffin-embedded tissue
were stained with periodic acid-Schiff (PAS) to analyze
tubulointerstitial and glomerular fibrosis by a computer-
based morphometric analysis. Renal sections were exam-
ined on a Leica DM LB2 light microscope (Leica
Microsystems, Wetzlar, Germany) connected to a PL-
A662 video camera and the Axiovision 2.05 image ana-
lysis system (both Karl Zeiss Vision GmbH, München,
Germany) using a 10 × 10 orthographic grid overlaid on
digital images. The relative degree of tubulointerstitial fi-
brotic lesions, i.e. matrix deposition, tubular atrophy and
dilation was calculated in 15 randomly-selected cortical
areas per animal observed at ×200 magnification. It is
expressed as percentage of the area affected in relation
to the total area analyzed. Glomerular matrix expansion
was evaluated by calculating the relative degree of the
mesangial matrix-occupying area (in percent) of 15
glomeruli from each rat.
Renal myofibroblast differentiation, macrophage infiltra-
tion and cell proliferation were analyzed on paraffin-
embedded tissues incubated with a primary mouse anti-α-SMA
or ED1 antibody (Serotec, Oxford, UK) in conjunction
with a standard APAAP technique (DakoCytomation,
Hamburg, Germany), and using a primary mouse anti-
PCNA-antibody (DakoCytomation) and a secondary goat
anti-mouse antibody coupled with the Envision™ staining
system (DakoCytomation), as previously described [16,18].
Immunohistochemistry for detecting type I collagen
was performed by using goat anti-type I collagen pri-
mary antibody (Southern Biotech, distributed by Biozol,
Eching, Germany). As a secondary antibody, horse-
radish peroxidase-conjugated rabbit anti-goat antibody
was used and visualized with AEC reagent (all Dako-
Cytomation, Glostrup, Denmark). Renal collagen I
deposition, myofibroblast differentiation, macrophage
infiltration and cell proliferation evaluated by collagen
and α-SMA positive staining, ED1- and PCNA-positive
cells, respectively in at least 15 glomerular sections and
at least 15 randomly-selected cortical areas from each
rat observed at ×200 magnification. Collagen I depos-
ition and myofibroblast were expressed as percentage
per area by applying the histomorphometric computer-
based Axiovision 4.1 image analysis system.
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fibronectin and TIMP-1
Glomeruli from individual rats were isolated by a graded
sieving technique (160, 125 and 71 μm mesh metal sieves),
as described previously [16]. For cultures of renal cortical
tissue, a piece of cortical tissue was weighed and minced
extensively with a razor blade [16]. Glomeruli or cortical
tissues were suspended in DMEM supplemented with 0.1
U/mL insulin, 100 U/mL penicillin and 100 μg/mL strepto-
mycin at a density of 2000 glomeruli/mL and 10 mg/mL,
respectively. After 48 h incubation at 37°C/5% CO2, super-
natants were harvested and stored at −20°C until further
analysis. TGF-β1 content of culture supernatant was mea-
sured after acid activation, using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems, Wiesbaden, Germany) according to the manufac-
turer’s instructions. TIMP-1 levels were analyzed using
another commercially available ELISA kit (R&D Systems,
Wiesbaden, Germany). Fibronectin was measured with a
modified competitive ELISA, according to published
methods [18]. Three samples from each rat were analyzed.
Quantitation of tubulointerstitial mRNA expression
Cortical total RNA was extracted with Trizol™ reagent
(Gibco BRL, Berlin, Germany) according to the manu-
facturer’s instructions. The mRNA expression was deter-
mined by a “two-step” reverse transcription-polymerase
chain reaction (RT-PCR) [18]. A cDNA copy was created
with reverse transcriptase from RNA PCR Core kit
(Roche, Applied Biosystems, New Jersey, USA). Real-time
PCR was performed using the LightCycler System and
SYBR Green I as dsDNA binding dye (Roche Diagnostics
GmbH, Mannheim). The following primer pairs were
used: PDGF-A (sense 5′-GCCTTGGAGACAAACCTG
AG-3′ and antisense 5′-AAATGACCGTCCTGGTCTT
G-3′), -B (sense 5′- ACACCTCAAACTCGGGTGAC-3′
and antisense 5′-TCAGTGCCTTCTTGTCATGG-3′), -C
(sense 5′- CCAAGAAATACGGTGCTGGT-3′ and anti-
sense 5′-CATCACTGGGCTCCTCAACT-3′), -D (sense
5′- CCCAGGAGAAAACACGGATA-3′ and antisense 5′-
CCTTATGGCCACACCATCTT-3′) and receptor-α (sense
5′-AGAAGATTGTGCCGCTGAGT-3′ and antisense 5′-T
CTTCGTTTCTGATTTCCAC-3′) and –β (sense 5′-ACAC
ATCAAATACGCGGACA-3′ and antisense 5′-GAGCACT
GGTGAGTCGTTGA-3′), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (sense 5′- CCATCTTCCAGGA
GCGAGAT-3′ and antisense 5′-GATGACCTTGCCCACA
GCCT-3′) as housekeeping gene were used as previously de-
scribed [21]. For analysis, a relative quantification method
was used as previously described [22].
Statistical analysis
The results are expressed as mean ± standard deviation
(SD). Our data were not normally distributed. Statisticalanalysis between groups was performed by Kruskal-
Wallis and subsequent Mann–Whitney U- testing. A
p-value lower than 0.05 was considered significant.
Results
Body weight, food and drug intake
At the end of the experiment, animals’ mean body
weights were 601 ± 68 g in the 2-K-Control, 544 ± 34 g
in the 1-K Control, 523 ± 40 g in the cGS and 497 ± 30 g
in the cGS + Imatinib group, respectively (p = NS be-
tween both cGS groups). Mean food and water intakes
did not significantly differ between the groups through-
out the experiment (data not shown).
Proteinuria, blood pressure and renal function
Before the start of therapy, nephritic animals were strati-
fied to start with equal levels of pre-treatment proteinuria
in the two diseased groups (Figure 1A) (cGS: 147 ±
30 mg/d, cGS + Imatinib: 146 ± 30 mg/d, P =NS). Urinary
protein loss increased gradually in untreated diseased ani-
mal groups during the experiment (week 10: 374 ±
149 mg/d and week 20: 495 ± 133 mg/d, p < 0.01 vs. Con-
trols). Administration of Imatinib slowed the deterioration
of urinary protein excretion. In week 20, proteinuria was
significantly lower in the Imatinib-treated animals (cGS +
Imatinib 366 ± 133 mg/d, p < 0.05 vs. cGS).
As shown in Figure 1B, systolic blood pressure was in-
creased slightly during the disease progression in the anti-
thy1-induced chronic glomerulosclerosis model (week 10:
128 ± 7 mmHg and week 20: 133 ± 7 mmHg, p < 0.05 vs.
Controls). In week 20, treatment with Imatinib reduced
systolic blood pressure significantly (123 ± 10 mmHg, p <
0.01 vs. cGS).
As shown in Table 1, animals with chronic anti-thy1
glomerulosclerosis showed significant increases in blood
creatinine (2.43 ± 2.12 mg/dL) and urea concentrations
(232 ± 182 mg/dL) and decrease in creatinine clearances
(0.24 ± 0.16 mL/min) (all P < 0.01 vs. 1-K Control),
indicating chronic renal insufficiency. Therapy with
Imatinib lowered plasma creatinine levels (−41%, 1.42 ±
1.13 mg/dL) and urea levels (−36%, 148 ± 109 mg/dL), and
preserved creatinine clearances (+25%, 0.32 ± 0.16 mL/min),
although they didn’t reach significance.
The histological photographs in Figures 2 and 3
provide characteristic overviews on the effects of
Imatinib treatment on renal matrix accumulation in anti-
thy1-induced chronic glomerulosclerosis. The most
pronounced actions of Imatinib were seen in the tubu-
lointerstitial compartment.
Tubulointerstitial matrix accumulation
As shown in Figures 4 and 3, there was a marked in-
crease in histological tubulointerstitial matrix score




































































Figure 1 Effects of Imatinib on time course of proteinuria (A)
and systolic blood pressure after 10 and 20 weeks (B) in
chronic anti-thy1 glomerulosclerosis (cGS). Administration of
Imatinib was started 7 days after injection of anti-thy1 antibody into
uni-nephrectomized rats (cGS + Imatinib). Nonnephritic animals with
(1-K Control) and without uninephrectomy (2-K Control) received an
injection with similar volumes of PBS. Blood pressure was measured
in conscious animals using a tail cuff method. Urine was collected
for 24 h at the indicated times, using metabolic cages. (*p < 0.05
and **p < 0.01 vs. cGS).
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ronectin (11392 ± 2498 ng/mL) and TIMP-1 (8320 ±
6812 pg/mL) when compared to non-nephritic control
animals (all p < 0.01 vs. Control) in week 20 after disease
induction. In turn, treatment with Imatinib reduced
histological tubulointerstitial matrix accumulation (−44%*,
30 ± 24%) and collagen I deposition (−86%***, 1.1 ± 0.7%),and protein expressions of TGF-β1 (−30%*, 206 ± 73
pg/mL), fibronectin (−23%**, 8744 ± 1383 ng/mL) and
TIMP-1 (−26%, 6120 ± 4086 pg/mL), respectively (*** p <
0.001, ** p < 0.01 and *p < 0.05 vs. cGS) (Figures 4 and 3).
Glomerular matrix accumulation
As shown in Figure 3 and Table 2, glomerular matrix pro-
tein accumulation was characterized by an increase in
histological matrix score (56 ± 17%), collagen I deposition
(3.8 ± 4.3%), and protein expression of TGF-β1 (101 ±
76 pg/mL) and fibronectin (5625 ± 1570 ng/mL) at the end
of the experiment (all p < 0.01 vs. 1-K Control). Administra-
tion of Imatinib lowered histological matrix accumulation
(−13%, 49 ± 17%), collagen I deposition (−95%, 0.2 ± 0.2%,
p < 0.05 vs. cGS), TGF-β1 (−17%, 84 ± 52 pg/mL) and fibro-
nectin (−13%, 4879 ± 1387 ng/mL).
Renal myofibroblast differentiation
As shown in Figure 5, uninephrectomized, nonnephritic
animals showed a low number of glomerular and tu-
bulointerstitial α-SMA expressing myofibroblasts (1-K
Control: 0.048 ± 0.048% and 0.038 ± 0.016%). In contrast,
rats with progressive anti-thy1-induced glomerulosclerosis
expressed marked increases in glomerular and tubulo-
interstitial α-SMA expression (1.25 ± 0.53% and 1.96 ±
0.93%, p < 0.001 vs. 1-K Controls). The number of α-
SMA-positive myofibroblasts in the glomeruli and
tubulointerstitium was reduced by −79% (0.26 ± 0.2%)
and −87% (0.26 ± 0.2%) after Imatinib treatment (p <
0.001 vs. cGS), respectively.
Renal macrophage infiltration and cell proliferation
Chronic anti-thy1-induced glomerulosclerosis was ac-
companied by prominent renal macrophage infiltration
and cell proliferation, both in the tubulointerstitial and
glomerular compartment. As shown in Figure 6, in the
group with progressive anti-thy1-induced glomerulos-
clerosis, ED1-positive cells indicating macrophages were
increased 32-fold at the tubulointerstitial level (20 ± 7.8
ED1 positive cells/cortical section), and 4-fold at the
glomerular level (2.6 ± 1.3 ED1 positive cells/glomerular
section), while PCNA-positive tubulointerstitial cells
indicating cell proliferation were elevated by 4-fold (33 ±
23 PCNA positive cells/cortical section) and PCNA-
positive glomerular cells by 2-fold (1.9 ± 0.6 PCNA posi-
tive cells/glomerular section), respectively (both p < 0.05
vs. Control). Treatment with Imatinib reduced both
tubulointerstitial and glomerular infiltration with macro-
phages (−36%**, 13 ± 3.4 ED1 positive cells/cortical sec-
tion and −45%*, 1.5 ± 0.7 ED1 positive cells/glomerular
section) and tubulointerstitial and glomerular prolifera-
tion of cells (−45%*, 18 ± 13 PCNA positive cells/cortical
section and −21%, 1.5 ± 0.5 PCNA positive cells/glom-
erular section)) (**p < 0.01 and *p < 0.05 vs. cGS).
Table 1 Effects of Imatinib on markers of renal function 20 weeks after induction of chronic anti-thy1
glomerulosclerosis (cGS)
Group/parameter Creatinine (mg/dL) Urea (mg/dL) GFR/100 g body weight mL/min
2-K Control 0.41 ± 0.12 42 ± 10 0.68 ± 0.04
1-K Control 0.49 ± 0.04 44 ± 6 0.49 ± 0.08
cGS 2.43 ± 2.12** 232 ± 182** 0.24 ± 0.16**
cGS + Imatinib 1.42 ± 1.13 148 ± 109 0.32 ± 0.16
Administration of Imatinib was started 7 days after injection of anti-thy1 antibody into uni-nephrectomized rats (cGS + Imatinib). Nonnephritic animals with (1-K
Control) and without uninephrectomy (2-K Control) received an injection with similar volumes of PBS. GFR is glomerular filtration rate. Plasma creatinine and urea
levels and creatinine clearance served as markers of excretory kidney function. (**p < 0.01 vs Controls).
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As shown in Table 3, compared to controls, the induction
of chronic progressive anti-thy1 induced glomerulosclerosis
increased mRNA expression of PDGF-A, B, C and D as
well as PDFG receptor-α and receptor-β. Treatment with
Imatinib had no significant effect on the mRNA expression
of PDGF signal transduction when compared to the un-
treated cGS group.A
C
Figure 2 Renal histology 20 weeks after induction of chronic anti-thy
7 days after injection of anti-thy1 antibody into uni-nephrectomized rats (c
uninephrectomy (2-K Control) received an injection with similar volumes o
sections from a normal control animal (A), an animal with uninephrectomi
Imatinib (D) treatment. Magnification ×400.Taken together, the present study demonstrates that in-
hibition of tyrosine kinases signal transduction limits the
progressive course of anti-thy1-induced chronic renal dis-
ease towards glomerulosclerosis, tubulointerstitial fibrosis
and renal insufficiency. Renoprotection by Imatinib was
associated with reductions in renal matrix accumulation,
TGF-β overproduction, myofibroblast differentiation, cell
proliferation and macrophage infiltration.B
D
1 glomerulosclerosis (cGS). Administration of Imatinib was started
GS + Imatinib). Nonnephritic animals with (1-K Control) and without
f PBS. Shown are characteristic periodic acid-schiff (PAS)-stained renal



































































































Figure 3 Glomerular and tubulointerstitial expression of collagen I 20 weeks after induction of chronic anti-thy1 glomerulosclerosis
(cGS). Representative photographs of immunhistochemically stained sections show a normal control animal (A), an animal with uninephrectomy
(B), an animal with anti-thy1-induced cGS without (C) and with Imatinib (D) treatment. Graphs depict the percentages of collagen I-positive
staining of at least 15 randomized tubulointerstitial (E) and glomerular sections (F) obtained by computer-based histomorphometry.
Administration of Imatinib was started 7 days after injection of anti-thy1 antibody into uni-nephrectomized rats (cGS + Imatinib). Nonnephritic
animals with (1-K Control) and without uninephrectomy (2-K Control) received an injection with similar volumes of PBS. Magnification ×200.
(*P < 0.05 and ***P < 0.001 vs. cGS).
Wang-Rosenke et al. BMC Nephrology 2013, 14:223 Page 7 of 13
http://www.biomedcentral.com/1471-2369/14/223Discussion
Tyrosine kinases regulate a wide variety of normal cell
processes, including metabolism, growth, differentiation
and apoptosis. Pathological activation of tyrosine kinases
may drive carcinogenesis, vascular remodeling and fibro-
genesis [23-25]. Imatinib was initially developed for its se-
lective action against the Bcr-Abl fusion protein, a key
driver of chronic myeloid leukemia [12]. The activities of
PDGF and c-Kit tyrosine kinase receptors are inhibited by
the drug, thus interfering with cell proliferation. Further-
more, c-Abl can promote fibrosis as an important down-
stream target of TGF-β [14]. This leads to the hypothesis
that tyrosine kinase inhibition of PDGF receptors and c-
Abl by Imatinib represents a single therapy capable ofinhibiting activity of two profibrotic growth factors TGF-β
and PDGF.
The present study was designed to explore the reno-
protective potential of the orally active tyrosine kinase
inhibitor Imatinib in a chronic model of progressive
mesangioproliferative glomerulonephritis. The major fin-
dings are 1) Imatinib remarkably limits the progressive
course of chronic anti-thy1 antibody-induced renal disease
as shown by functional and morphological estimates; 2)
the renoprotective action of Imatinib involved beneficial ef-
fects on key pathways of progressive renal disease such as
decreased TGF-beta protein expression, matrix protein ac-
cumulation, renal cell proliferation, myofibroblast activa-





























































































































































































Figure 4 Effects of Imatinib on tubulointerstitial matrix protein expression 20 weeks after induction of chronic anti-thy1
glomerulosclerosis (cGS). Shown are tubulointerstitial matrix accumulation (A) and protein expression of TGF-β1 (B), fibronectin (C) and TIMP-1
(D). Administration of Imatinib was started 7 days after injection of anti-thy1 antibody into uni-nephrectomized rats (cGS + Imatinib).
Nonnephritic animals with (1-K Control) and without uninephrectomy (2-K Control) received an injection with similar volumes of PBS. The relative
degree of matrix accumulation was calculated by computer-based morphometric analysis. Matrix protein production was determined in
extensively minced individual cortical tissues cultured at a density of 10 mg/mL for 48 h (*p < 0.05 and **p < 0.01 vs. cGS).
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and less in the glomerular space. In the following we will
discuss the relevance and implications of these findings.
Previous studies have shown that beneficial effects of






2-K Control 21 ± 4 22
1-K Control 24 ± 4 28
cGS 56 ± 17** 10
cGS + Imatinib 49 ± 17 84
Shown are glomerular matrix accumulation and protein expression of TGF-β1 and f
thy1 antibody into uni-nephrectomized rats (cGS + Imatinib). Nonnephritic animals
injection with similar volumes of PBS. Matrix expansion was scored on PAS-stained
density of 2000 per mL for 48 h. (**p < 0.01 vs. Controls).anti-thy1 glomerulonephritis of the rat [15], lupus neph-
ritis [26,27], hypertensive nephropathy [28], diabetic
nephropathy [19], unilateral ureteral obstruction [29],
chronic allograft nephropathy [30]. In acute anti-thy1





± 22 2600 ± 182
± 30 2695 ± 356
1 ± 76** 5625 ± 1570**
± 52 4879 ± 1387
ibronectin. Administration of Imatinib was started 7 days after injection of anti-
with (1-K Control) and without uninephrectomy (2-K Control) received an
































































































Figure 5 Effects of Imatinib on tubulointerstitial (A) and glomerular (B) myofibroblast differentiation 20 weeks after induction of
chronic anti-thy1 glomerulosclerosis (cGS). Administration of Imatinib was started 7 days after injection of anti-thy1 antibody into uni-
nephrectomized rats (cGS + Imatinib). Nonnephritic animals with (1-K Control) and without uninephrectomy (2-K Control) received an injection
with similar volumes of PBS. Analysis was performed using a primary α-SMA-antibody for myofibroblast. Data are expressed as percentage of
α-SMA-positive expression per cortical section observed at ×200 magnification and per glomerular cross section (***p < 0.001 vs. cGS).
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receptor tyrosine kinase blockade with STI 571 was as-
sociated with significant reductions in mesangial cell
proliferation, the number of activated (alpha-smooth
muscle positive) mesangial cells, and glomerular type IV
collagen deposition. These findings are now expanded
into a chronic renal disease model with a distinct injuri-
ous glomerular insult in the beginning and subsequent
progressive tubulointerstitial fibrosis and renal insuffi-
ciency driven by, not primarily immune-mediated, rather
autonomously intrarenal mechanisms, which are shared
by many other chronic kidney diseases and are in a line
with the concept that a common final pathway underlies
the advance of renal disease. Compared with the daily
intraperitoneal dose 50 mg/kg in the acute anti-thy1
model, Imatinib was given orally in relative low dose
10 mg/kg, which was clinically more relevant und com-
bined with less side effects.
This contrasts to diabetic and hypertensive nephropa-
thy in which extrarenal stimuli, such as high blood pres-
sure or hyperglycaemia damage the kidney continuously
and thereby maintain disease progress. The same applies
to lupus nephritis and chronic allograft nephropathy, in
which the ongoing injurious stimuli are of primary im-
munologic nature. In this sense, the model of anti-thy1-
induced, chronic progressive renal fibrosis may be seen
as representation of patients with primary glomerular
disease who progress to end-stage renal disease after a
single episode of glomerulonephritis. In addition, the
findings of this study put a new perspective of the thera-
peutic mechanism of Imatinib on chronic renal disease.
There is a vast of evidence that TGF-β and PDGF closely
and jointly mediate and promote the progression of renaldisease. In this study, we found a marked reduction in
renal TGF-β1 protein expression by the inhibitory action
of Imatinib. There are at least two mechanisms contribut-
ing to the reduction of TGF-β. PDGF and TGF-β interact
with each other and have overlapping biologic activities. In
vitro, the anti-TGF-β neutralizing antibody clearly in-
hibited the stimulatory effect of PDGF on type IV collagen
production and PDGF also stimulated TGF-beta produc-
tion in human mesangial cells in a dose-dependent manner
[31]. It could also be explained by inhibited downstream
target of TGF-β, the Bcr-Abl tyrosine kinase, by Imatinib
treatment. In experimental bleomycin-mediated lung fi-
brosis and unilateral obstructive nephropathy models, the
treatment of Imatinib reduces the fibrogenesis via in-
hibiting fibroblast proliferation which is mediated by the
c-abl activation through TGF-β [14,29].
Furthermore, the number of α-SMA-positive myofibro-
blast was reduced by Imatinib treatment in glomeruli and
tubulointerstitium. This is associated with inhibition of
TGF-β and PDGF through the administration of Imatinib,
since both growth factors participate actively in myo-
fibroblast differentiation. In addition, there was a reduction
in renal macrophage infiltration with Imatinib. Importance
of PDGF isoforms in the development of kidney diseases
was confirmed by a number of in vitro experiments, which
showed that PDGF may function as a potent chemoattract-
ant for mesangial cells and leukocytes [32,33]. PDGF and
TGF-β are mainly produced by infiltrating inflammatory
cells under pathological conditions [21,34]. Therefore, treat-
ment of Imatinib decreased macrophage infiltration, which
conversely resulted in a decrease in PDGF and TGF-β pro-
duction within the renal tissue. Both may have contributed

























































































































































































Figure 6 Effects of Imatinib on tubulointerstitial and glomerular macrophage infiltration (A, B) and cell proliferation (C, D) 20 weeks
after induction of chronic anti-thy1 glomerulosclerosis (cGS). Administration of Imatinib was started 7 days after injection of anti-thy1
antibody into uni-nephrectomized rats (cGS + Imatinib). Nonnephritic animals with (1-K Control) and without uninephrectomy (2-K Control)
received an injection with similar volumes of PBS. Analysis was performed using a primary ED1-antibody for macrophages and a primary PCNA-
antibody for proliferating cells. Data are expressed as cells per cortical section observed at ×200 magnification and per glomerular cross section
(*p < 0.05 and **p < 0.01 vs. cGS).
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Imatinib. Renal cell proliferation precedes extracellular
matrix protein expansion in many kidney diseases. Exogen-
ous administration of PDGF isoforms induced in vitro
mesangial cells contraction and rapid proliferation [35,36];
and resulted in mild mesangial cell proliferation in normal
rats [21]. Interestingly, the administration of Imatinib hadTable 3 Effects of Imatinib on tubulointerstitial mRNA expres
induction of chronic anti-thy1 glomerulosclerosis (cGS)
Group/parameter PDGF-A (%) PDGF-B (%) PDG
2-K Control 98 ± 22 111 ± 56 101 ±
1-K Control 90 ± 4 114 ± 50 89 ±
cGS 306 ± 318* 263 ± 172* 83 ±
cGS + Imatinib 172 ± 56** 224 ± 96* 84 ±
Shown are tubulointerstitial mRNA expressions of PDGF-A, -B, -C, -D and receptor-a
anti-thy1 antibody into uni-nephrectomized rats (cGS + Imatinib). Nonnephritic anim
injection with similar volumes of PBS. mRNA was analyzed by a real-time polymeras
dehydrogenase (GAPDH) as housekeeping gene. (**p < 0.01 and *p < 0.05 vs. Controno significant effects on the mRNA expression of PDGF
isoforms and its receptors in our study. We think Imatinib
may interfere mostly with the downstream of PDGF signal
transduction through the inhibition of PDGF receptor tyro-
sine kinase, and hence has no significant effects on up-
stream mRNA expression. Therefore, this study in chronic
anti-thy1 mesangioproliferative glomerulosclerosis provedsions of PDGF signal transduction 20 weeks after
F-C (%) PDGF-D (%) PDGF-α (%) PDGF-β (%)
50 126 ± 42 106 ± 42 118 ± 74
18 102 ± 50 91 ± 66 75 ± 22
66 265 ± 186* 383 ± 222** 307 ± 179**
23 261 ± 126** 355 ± 186** 305 ± 156**
lpha and –beta. Administration of Imatinib was started 7 days after injection of
als with (1-K Control) and without uninephrectomy (2-K Control) received an
e chain reaction (PCR) method using glyceraldehydes-3-phosphate
ls).
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Imatinib directly or indirectly interferes with multiple key
pathways to slow the progression of chronic renal disease.
In the present study, benefits at the glomerular level were
more moderate than in the tubulointerstitium. We think
this could be explained by a beginning of Imatinib therapy
as late as 7 days after injection of anti-thy1 antibody, when
the glomerular injuries were already established. This view
is supported by the renoprotective effects on glomerular
mesangioproliferation in acute anti-thy1 induced glomer-
ulonephritis when therapy was started as early as 24 hours
after anti-thy1 antibody injection [15].
Systolic blood pressure was significantly lower in the
Imatinib-treated animals than in the untreated chronic
glomerulosclerosis animals in week 20 after disease
induction. This may have contributed to the renoprotection
of Imatinib treatment. According to its primary pharmaco-
logical action, tyrosine kinase inhibitors possess no direct
effect on blood pressure. Therefore, it is likely that the
lower blood pressure with Imatinib in this study was medi-
ated indirectly through less renal damage and fibrosis.
So far, there have been undertaken different strategies to
block TGF-β and PDGF action in various renal disease
models. The administration of neutralizing antibodies
against PDGF isoforms and its receptors (PDGF-A, -B,
-C,-D, PDGF-Rβ) [37-40] and oligonucleotide aptamer an-
tagonist against PDGF [41,42] have already been described.
Neutralizing the actions of TGF-beta with either an anti-
body or the proteoglycan decorin has been shown to pre-
vent excessive matrix accumulation after tissue injury
[43,44]. PDGF antagonists mentioned above had a benefi-
cial effect on renal disease in vivo experiments in spontan-
eously hypertensive rats, model of unilateral ureteral
obstruction, streptozotocin-induced diabetes and anti-thy1
induced glomerulonephritis [7]. Compared to other PDGF
antagonists with unconvinient application, expensive costs
and immunological complications, orally administered
Imatinib is well absorbed and has an absolute bioavailability
of 98% without high production costs and immunological
complications. In this context we would like to point out
that Imatinib was even effective in a relative low dose of
10 mg/day/Kg in chronic anti-thy 1 glomeruloslerosis as
compared to other renal disease models [15,26-29].
Imatinib, the first generation to be established as c-abl
and PDGF receptor inhibitor, is considered standard front-
line therapy for the management of patients with chronic
myeloid leukemia. However, there has been concern over
the emergence of resistance to imatinib, and some patients
fail to respond or are intolerant of imatinib therapy be-
cause of untoward toxicity. The side effects of Imatinib
are dose-dependent and include oedema, muscle cramps,
diarrhea, and bone marrow toxicity [45]. Imatinib might
also slightly increase the risk of congestive heart failure,
especially in patients with a previous history of heartdisease [46]. Dasatinib, nilotinib and Bosutinib, the second
gerneration inhibitors of c-abl and PDGF receptors, serve
as salvage therapies for the treatment of refractory chronic
myeloid leukemia as well as patients with intolerance to
Imatinib [47,48]. Although these agents are active, third-
generation TKIs are under development for patients who
either have failed sequential therapy with at least two TKIs
or carry the highly resistant T315I mutation. Some of
these agents have already shown promising clinical activ-
ity. However, longer follow-up is warranted to unveil the
potential of these agents in progressive fibrotic changes
and their unwanted toxicity.
Conclusions
PDGF plays a major role in stimulating the replication,
survival and migration of myofibroblasts, while TGF-β1
primarily functions in fibrogenesis to stimulate collagen
deposition by newly replicated myofibroblasts. In chro-
nic renal disease, both cytokines play a dependently or
independently role in disease progression. In a model of
chronic anti-thy1-induced mesangioproliferative glomeru-
losclerosis, we found that administration of Imatinib slows
its progressive course toward chronic renal fibrosis and in-
sufficiency. The beneficial effects of Imatinib are associ-
ated with improvement in proteinuria, extracelluar matrix
protein accumulation, renal myofibroblast differentiation,
renal cell proliferation and macrophage infiltration, which
are crucial for the progression of chronic renal disease.
The renoprotective actions may involve the antagonism of
PDGF receptor tyrosine kinase and inhibition of TGF-β
mediated by bcr-Abl activation. These findings suggest the
tyrosine kinase inhibitors, such as Imatinib, may be an ef-
fective approach in slowing the progression of chronic
glomerular disease.
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